Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Imaging the inflammatory phenotype in migraine

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. The economic and personal burden of cluster headache: a controlled cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Headache provocation by nitric oxide in men who have never experienced a headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Reply to 'Paracetamol use in pregnancy - neglecting context promotes misinterpretation'

    Publikation: Bidrag til tidsskriftLetterpeer review

  4. Low adherence to the guideline for the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

BACKGROUND: The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates both the CGRP-R and structurally related amylin 1 receptor (AMY1-R). The relative effect of erenumab and the small-molecule CGRP-R antagonist, rimegepant, towards the CGRP-R and AMY-R needs to be further characterized.

METHODS: The effect of CGRP and two CGRP-R antagonists were examined in Xenopus laevis oocytes expressing human CGRP-R, human AMY1-R and their subunits.

RESULTS: CGRP administered to receptor expressing oocytes induced a concentration-dependent increase in current with the order of potency CGRP-R> > AMY1-R > calcitonin receptor (CTR). There was no effect on single components of the CGRP-R; calcitonin receptor-like receptor and receptor activity-modifying protein 1. Amylin was only effective on AMY1-R and CTR. Inhibition potencies (pIC50 values) for erenumab on CGRP induced currents were 10.86 and 9.35 for CGRP-R and AMY1-R, respectively. Rimegepant inhibited CGRP induced currents with pIC50 values of 11.30 and 9.91 for CGRP-R and AMY1-R, respectively.

CONCLUSION: Our results demonstrate that erenumab and rimegepant are potent antagonists of CGRP-R and AMY1-R with 32- and 25-times preference for the CGRP-R over the AMY1-R, respectively. It is discussed if this difference in affinity between the two receptors is the likely reason why constipation is a common and serious adverse effect during CGRP-R antagonism but less so with CGRP binding antibodies.

TidsskriftThe Journal of Headache and Pain Online
Udgave nummer1
Sider (fra-til)59
StatusUdgivet - 26 maj 2022

Bibliografisk note

© 2022. The Author(s).

ID: 78263815